EXT1 Inhibitors
EXT1 inhibitors belong to a distinct and well-defined chemical class that plays a significant role in modulating cellular processes. These inhibitors specifically target and interact with the EXT1 enzyme, which is a vital component of glycosaminoglycan (GAG) biosynthesis. GAGs are complex carbohydrate chains that are integral to various biological functions, such as cell signaling, adhesion, and tissue development. The EXT1 enzyme is crucial for initiating the elongation of GAG chains, a process essential for the proper formation and maintenance of the extracellular matrix, which provides structural support to cells and tissues. Structurally, EXT1 inhibitors are designed to bind to the active site of the EXT1 enzyme, thereby impeding its catalytic activity. By doing so, these inhibitors can effectively modulate the biosynthesis of GAG chains, leading to altered extracellular matrix composition. This, in turn, can influence cellular behaviors, adhesion properties, and intercellular communication processes. The intricate involvement of GAGs in diverse physiological processes underscores the importance of EXT1 inhibitors as valuable tools for probing these intricate molecular mechanisms.
Research into EXT1 inhibitors has provided valuable insights into the underlying biochemistry of GAG biosynthesis and its associated cellular effects. By selectively inhibiting the EXT1 enzyme, researchers have been able to unravel the nuanced roles of GAGs in various cellular and developmental contexts. The development and study of EXT1 inhibitors have far-reaching implications in deciphering the intricate interactions between cells and their microenvironment, shedding light on fundamental aspects of cell biology and tissue homeostasis. In conclusion, EXT1 inhibitors represent a well-defined class of compounds that exhibit a precise mode of action targeting the EXT1 enzyme involved in GAG biosynthesis. These inhibitors play a pivotal role in elucidating the complex interplay between GAGs and cellular processes, thereby advancing our understanding of essential biological mechanisms.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
It blocks the EGFR tyrosine kinase domain, disrupting downstream signaling pathways involved in cell proliferation. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Similar to gefitinib, erlotinib is used in NSCLC and pancreatic cancer. It competitively inhibits the EGFR tyrosine kinase activity, reducing cell growth and division. | ||||||
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
Approved for NSCLC, afatinib targets not only EGFR but also other members of the ErbB family of receptors. It forms a covalent bond with the receptor, preventing signaling. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Used for NSCLC with specific EGFR mutations, osimertinib selectively inhibits the mutant form of the receptor responsible for drug resistance. | ||||||
Neratinib | 698387-09-6 | sc-364549 sc-364549A sc-364549B sc-364549C sc-364549D | 5 mg 25 mg 100 mg 500 mg 1 g | $92.00 $214.00 $383.00 $755.00 $1250.00 | 4 | |
This inhibitor targets both EGFR and HER2, two receptors often implicated in breast cancer. Neratinib forms irreversible bonds with these receptors to suppress their signaling. | ||||||
Lapatinib ditosylate | 388082-78-8 | sc-202205B sc-202205 sc-202205A | 5 mg 10 mg 25 mg | $49.00 $77.00 $117.00 | 15 | |
Another dual inhibitor, lapatinib targets both EGFR and HER2, particularly in HER2-positive breast cancers. It works by blocking the intracellular kinase domains of these receptors. | ||||||